Sign In
St. John Health System
Lab Catalog


Index:

KRAS Mutation Analysis (K-ras)

Order Name KRAS MUTAT
Test Number: 9100025
Revision Date 08/13/2012
Test Name Methodology LOINC Code
KRAS Mutation Analysis (K-ras)
Polymerase Chain Reaction  
SPECIMEN REQUIREMENTS
Specimen Specimen Volume (min) Specimen Type Specimen Container Transport Environment
Preferred See Below Tissue Paraffin Block Room Temperature
Instructions Formalin fixed paraffin embedded tissue. Tissue source and block ID containing tumor are required on the requisition form.
Pathology permission is required for any alternate sample types.
GENERAL INFORMATION
Testing Schedule Mon, Thr 
Expected TAT 11-13 Days 
Clinical Use Activating Ras mutations can be found in human malignancies with overall frequency of 15-20%. A high incidence of Ras gene mutations has been reported in 80-90% malignant tumors of the pancreas, 30-60% in colon rectal carcinomas, and in 18-30% of hematopoietic neoplasia of myeloid origin. Ras proteins were shown to influence proliferation, differentiation, transformation, and apoptosis by relaying mitogenic and growth signals into the cytoplasma and the nucleolus. Mutations leading to an amino acid substitution at positions 12,13 and 61 are the most common in naturally occurring neoplasms and are frequent in adenocarcinomas of the pancreas, colon, and certain types of hematological malignancies. 
Notes Fresh Tissue may be submitted for processing in our histology department or tissue blocks may be used from earlier hospital stays or other encounters, but the KRAS Mutation order must be ordered on the patient's current encounter specific to the ordering physician and client account.
CPT Code(s) 83891, 83892x2, 83898x2, 83904x4, 83909x2, 83912
Service Provided By Labcorp Oklahoma, Inc.
Lab Section Reference Lab